United States Health Insurance: Premium Per Member Per Month data was reported at 364.000 USD in Sep 2024. This stayed constant from the previous number of 364.000 USD for Jun 2024. United States Health Insurance: Premium Per Member Per Month data is updated quarterly, averaging 262.000 USD from Mar 2012 (Median) to Sep 2024, with 51 observations. The data reached an all-time high of 364.000 USD in Sep 2024 and a record low of 178.000 USD in Sep 2013. United States Health Insurance: Premium Per Member Per Month data remains active status in CEIC and is reported by National Association of Insurance Commissioners. The data is categorized under Global Database’s United States – Table US.RG017: Health Insurance: Industry Financial Snapshots.

Income-Before-Tax Time Series for Elevance Health Inc. Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Change-To-Inventory Time Series for Elevance Health Inc. Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

The Congressional District Health Dashboard (CDHD) was launched in 2023 to present actionable and nonpartisan data on health, drivers of health, and health equity for all 435 congressional districts across the United States and Washington DC. Like the City Health Dashboard, available metrics include health outcomes, social and economic factors, health behavior, physical environment, and clinical care to enable policymakers, advocates, and community members to identify their strengths and challenges and drive positive change.

The CDHD incorporates the 2022 re-drawn district boundaries based on the 2020 census and corresponding to the 118th Congress (beginning January 2023).

This United States Environmental Protection Agency (US EPA) feature layer represents monitoring site data, updated hourly concentrations and Air Quality Index (AQI) values for the latest hour received from monitoring sites that report to AirNow.Map and forecast data are collected using federal reference or equivalent monitoring techniques or techniques approved by the state, local or tribal monitoring agencies. To maintain "real-time" maps, the data are displayed after the end of each hour. Although preliminary data quality assessments are performed, the data in AirNow are not fully verified and validated through the quality assurance procedures monitoring organizations used to officially submit and certify data on the EPA Air Quality System (AQS).This data sharing, and centralization creates a one-stop source for real-time and forecast air quality data. The benefits include quality control, national reporting consistency, access to automated mapping methods, and data distribution to the public and other data systems. The U.S. Environmental Protection Agency, National Oceanic and Atmospheric Administration, National Park Service, tribal, state, and local agencies developed the AirNow system to provide the public with easy access to national air quality information. State and local agencies report the Air Quality Index (AQI) for cities across the US and parts of Canada and Mexico. AirNow data are used only to report the AQI, not to formulate or support regulation, guidance or any other EPA decision or position.About the AQIThe Air Quality Index (AQI) is an index for reporting daily air quality. It tells you how clean or polluted your air is, and what associated health effects might be a concern for you. The AQI focuses on health effects you may experience within a few hours or days after breathing polluted air. EPA calculates the AQI for five major air pollutants regulated by the Clean Air Act: ground-level ozone, particle pollution (also known as particulate matter), carbon monoxide, sulfur dioxide, and nitrogen dioxide. For each of these pollutants, EPA has established national air quality standards to protect public health. Ground-level ozone and airborne particles (often referred to as "particulate matter") are the two pollutants that pose the greatest threat to human health in this country.A number of factors influence ozone formation, including emissions from cars, trucks, buses, power plants, and industries, along with weather conditions. Weather is especially favorable for ozone formation when it’s hot, dry and sunny, and winds are calm and light. Federal and state regulations, including regulations for power plants, vehicles and fuels, are helping reduce ozone pollution nationwide.Fine particle pollution (or "particulate matter") can be emitted directly from cars, trucks, buses, power plants and industries, along with wildfires and woodstoves. But it also forms from chemical reactions of other pollutants in the air. Particle pollution can be high at different times of year, depending on where you live. In some areas, for example, colder winters can lead to increased particle pollution emissions from woodstove use, and stagnant weather conditions with calm and light winds can trap PM2.5 pollution near emission sources. Federal and state rules are helping reduce fine particle pollution, including clean diesel rules for vehicles and fuels, and rules to reduce pollution from power plants, industries, locomotives, and marine vessels, among others.How Does the AQI Work?Think of the AQI as a yardstick that runs from 0 to 500. The higher the AQI value, the greater the level of air pollution and the greater the health concern. For example, an AQI value of 50 represents good air quality with little potential to affect public health, while an AQI value over 300 represents hazardous air quality.An AQI value of 100 generally corresponds to the national air quality standard for the pollutant, which is the level EPA has set to protect public health. AQI values below 100 are generally thought of as satisfactory. When AQI values are above 100, air quality is considered to be unhealthy-at first for certain sensitive groups of people, then for everyone as AQI values get higher.Understanding the AQIThe purpose of the AQI is to help you understand what local air quality means to your health. To make it easier to understand, the AQI is divided into six categories:Air Quality Index(AQI) ValuesLevels of Health ConcernColorsWhen the AQI is in this range:..air quality conditions are:...as symbolized by this color:0 to 50GoodGreen51 to 100ModerateYellow101 to 150Unhealthy for Sensitive GroupsOrange151 to 200UnhealthyRed201 to 300Very UnhealthyPurple301 to 500HazardousMaroonNote: Values above 500 are considered Beyond the AQI. Follow recommendations for the Hazardous category. Additional information on reducing exposure to extremely high levels of particle pollution is available here.Each category corresponds to a different level of health concern. The six levels of health concern and what they mean are:"Good" AQI is 0 to 50. Air quality is considered satisfactory, and air pollution poses little or no risk."Moderate" AQI is 51 to 100. Air quality is acceptable; however, for some pollutants there may be a moderate health concern for a very small number of people. For example, people who are unusually sensitive to ozone may experience respiratory symptoms."Unhealthy for Sensitive Groups" AQI is 101 to 150. Although general public is not likely to be affected at this AQI range, people with lung disease, older adults and children are at a greater risk from exposure to ozone, whereas persons with heart and lung disease, older adults and children are at greater risk from the presence of particles in the air."Unhealthy" AQI is 151 to 200. Everyone may begin to experience some adverse health effects, and members of the sensitive groups may experience more serious effects."Very Unhealthy" AQI is 201 to 300. This would trigger a health alert signifying that everyone may experience more serious health effects."Hazardous" AQI greater than 300. This would trigger a health warnings of emergency conditions. The entire population is more likely to be affected.AQI colorsEPA has assigned a specific color to each AQI category to make it easier for people to understand quickly whether air pollution is reaching unhealthy levels in their communities. For example, the color orange means that conditions are "unhealthy for sensitive groups," while red means that conditions may be "unhealthy for everyone," and so on.Air Quality Index Levels of Health ConcernNumericalValueMeaningGood0 to 50Air quality is considered satisfactory, and air pollution poses little or no risk.Moderate51 to 100Air quality is acceptable; however, for some pollutants there may be a moderate health concern for a very small number of people who are unusually sensitive to air pollution.Unhealthy for Sensitive Groups101 to 150Members of sensitive groups may experience health effects. The general public is not likely to be affected.Unhealthy151 to 200Everyone may begin to experience health effects; members of sensitive groups may experience more serious health effects.Very Unhealthy201 to 300Health alert: everyone may experience more serious health effects.Hazardous301 to 500Health warnings of emergency conditions. The entire population is more likely to be affected.Note: Values above 500 are considered Beyond the AQI. Follow recommendations for the "Hazardous category." Additional information on reducing exposure to extremely high levels of particle pollution is available here.

NOTE: As of 12/17/2024, this dataset is no longer updated. Please use ASPR Treatments Locator. This dataset displays pharmacies, clinics, and other locations with safe and effective COVID-19 medications. These medications require a prescription from a healthcare provider. Some locations, known as Test to Treat sites, give you the option to get tested, get assessed by a healthcare provider, and receive treatment – all in one visit. COVID-19 medications may be available at additional locations that are not shown in this dataset. The locations displayed have either self-attested they have inventory of Paxlovid (nirmatrelvir packaged with ritonavir), Lagevrio (molnupiravir), or Veklury (Remdesivir) within at least the last two months and/or reported participation in the Paxlovid Patient Assistance Program. Sites that have not reported in the last two weeks display a notification, "Inventory has not been reported in the last 2 weeks. Please contact the provider to make sure the product is available." Outpatient COVID-19 medications may be available at additional locations not listed on this website. All therapeutics identified in the locator not approved by the FDA must be used in alignment with the terms of the respective product’s Emergency Use Authorization. Visit COVID-19 Treatments and Therapeutics for more information on all treatment options. This website identifies sites that have commercially purchased inventory of COVID-19 treatments and, in some cases, may identify sites that have remaining, no-cost U.S. government distributed supply. Some sites may charge for services not covered by insurance. Some sites may offer telehealth services. This website is intended for informational purposes only and does not serve as an endorsement or recommendation for use of any of the locations listed on the sites. Clarification for DoD Facilities: Those individuals eligible for care in an MTF include Active Duty Service Members (ADSMs), covered beneficiaries enrolled in TRICARE Prime or Select, including TRICARE Reserve Select (TRS), TRICARE Retired Reserve (TRR) and TRICARE Young Adult (TYA) participants, TRICARE for Life beneficiaries, and individuals otherwise entitled by law to MTF care (e.g., regular retired members and their dependents who are not enrolled in TRICARE but who are otherwise eligible for MTF space-available care, certain foreign military members and their families registered in DEERS, and others).

The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2015 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.

The WORLD Policy Analysis Center (WORLD) is committed to improving the quantity and quality of globally comparative data available to policymakers, citizens, civil society, and researchers on laws and policies that work to support human rights, including economic opportunity, social and civic engagement, human health, development, well-being, and equity. The WORLD Paid Leave and Job Protection for Parents, People Who Are Sick and People Who Have Sick Family Members in the United States 2022 dataset was created to assess progress on laws guaranteeing paid leave that matters to health and economic security through a systematic review of legislation governing paid leave and job protection across all US states, the District of Columbia and Puerto Rico as of December 2022. The dataset covers paid leave for birthing parents, paid leave for non-birth parents, paid medical leave, and paid family leave for serious illness and key features of each type of leave including, duration, wage replacement rate, eligibility criteria, and job protection criteria.

The purpose of the U.S. Department of Health & Human Services (HHS) Data Governance Board (DGB) is to serve as the Department’s principal data governance forum and decision-making body for managing HHS’ data as a strategic asset and to support HHS in meeting its mission and agency priorities, including implementation of the Evidence Act.

The HHS DGB currently meets monthly to support these activities.

This dataset serves to communicate to the public the members of the HHS DGB, as required by the Federal Data Strategy.

The location and facility information for doctors who participate in NYC Regional Electronic Adoption Center for Health (REACH), which assists providers in adopting technology and methods for electronic health records.

The PATH Study was launched in 2011 to inform the Food and Drug Administration's regulatory activities under the Family Smoking Prevention and Tobacco Control Act (TCA). The PATH Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA). The study sampled over 150,000 mailing addresses across the United States to create a national sample of people who use or do not use tobacco. 45,971 adults and youth constitute the first (baseline) wave, Wave 1, of data collected by this longitudinal cohort study. These 45,971 adults and youth along with 7,207 "shadow youth" (youth ages 9 to 11 sampled at Wave 1) make up the 53,178 participants that constitute the Wave 1 Cohort. Respondents are asked to complete an interview at each follow-up wave. Youth who turn 18 by the current wave of data collection are considered "aged-up adults" and are invited to complete the Adult Interview. Additionally, "shadow youth" are considered "aged-up youth" upon turning 12 years old, when they are asked to complete an interview after parental consent. At Wave 4, a probability sample of 14,098 adults, youth, and shadow youth ages 10 to 11 was selected from the civilian, noninstitutionalized population (CNP) at the time of Wave 4. This sample was recruited from residential addresses not selected for Wave 1 in the same sampled Primary Sampling Unit (PSU)s and segments using similar within-household sampling procedures. This "replenishment sample" was combined for estimation and analysis purposes with Wave 4 adult and youth respondents from the Wave 1 Cohort who were in the CNP at the time of Wave 4. This combined set of Wave 4 participants, 52,731 participants in total, forms the Wave 4 Cohort. At Wave 7, a probability sample of 14,863 adults, youth, and shadow youth ages 9 to 11 was selected from the CNP at the time of Wave 7. This sample was recruited from residential addresses not selected for Wave 1 or Wave 4 in the same sampled PSUs and segments using similar within-household sampling procedures. This "second replenishment sample" was combined for estimation and analysis purposes with the Wave 7 adult and youth respondents from the Wave 4 Cohorts who were at least age 15 and in the CNP at the time of Wave 7. This combined set of Wave 7 participants, 46,169 participants in total, forms the Wave 7 Cohort. Please refer to the Restricted-Use Files User Guide that provides further details about children designated as "shadow youth" and the formation of the Wave 1, Wave 4, and Wave 7 Cohorts. Dataset 0002 (DS0002) contains the data from the State Design Data. This file contains 7 variables and 82,139 cases. The state identifier in the State Design file reflects the participant's state of residence at the time of selection and recruitment for the PATH Study. Dataset 1011 (DS1011) contains the data from the Wave 1 Adult Questionnaire. This data file contains 2,021 variables and 32,320 cases. Each of the cases represents a single, completed interview. Dataset 1012 (DS1012) contains the data from the Wave 1 Youth and Parent Questionnaire. This file contains 1,431 variables and 13,651 cases. Dataset 1411 (DS1411) contains the Wave 1 State Identifier data for Adults and has 5 variables and 32,320 cases. Dataset 1412 (DS1412) contains the Wave 1 State Identifier data for Youth (and Parents) and has 5 variables and 13,651 cases. The same 5 variables are in each State Identifier dataset, including PERSONID for linking the State Identifier to the questionnaire and biomarker data and 3 variables designating the state (state Federal Information Processing System (FIPS), state abbreviation, and full name of the state). The State Identifier values in these datasets represent participants' state of residence at the time of Wave 1, which is also their state of residence at the time of recruitment. Dataset 1611 (DS1611) contains the Tobacco Universal Product Code (UPC) data from Wave 1. This data file contains 32 variables and 8,601 cases. This file contains UPC values on the packages of tobacco products used or in the possession of adult respondents at the time of Wave 1. The UPC values can be used to identify and validate the specific products used by respondents and augment the analyses of the characteristics of tobacco products used

Conducted by the National Association of County and City Health Officials (NACCHO), the purpose of this survey of local health departments (LHDs) was to advance and support the development of a database for LHDs to describe and understand their structure, function, and capacities. A core set of questions was submitted to every LHD. In addition, some LHDs received one of two randomly assigned modules of supplemental questions. Data from the National Profile of Local Health Departments survey are used by: LHD staff members to compare their LHD or those within their states to others nationwide; Policymakers at the local, state, and federal levels to inform public health policy and support projects to improve local public health practice; Universities to educate future public health workforce members about LHDs; Researchers to address questions about public health practice; andNACCHO staff to develop programs and resources that meet the needs of LHDs and to advocate effectively for LHDs. Data included as part of this collection includes the Restricted-Use (Restricted-Use Level 2) data of the National Profile of Local Health Departments 2016 study. The dataset includes 1930 cases for 1116 variables.

Total-Current-Assets Time Series for Elevance Health Inc. Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2012 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.

DiD analysis results of countries with high UHC index values (UHC SCI ≥80) vs. all other countries (UHC SCI

KAV 7013 cover memo

The Medical Expenditure Panel Survey (MEPS) Household Component collects data on all members of sample households from selected communities across the United States. With the MEPS-HC Data Tools, users can explore trends and cross-sectional bar charts for nationally representative estimates of household medical utilization and expenditures, demographic and socioeconomic characteristics, health insurance coverage, accessibility and quality of care, treated medical conditions, and prescribed medicine purchases.

The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. Detailed NSDUH 2008 documentation http://www.samhsa.gov/data/2k12/NSDUH2008MRB/Index.aspx is available from SAMHSA. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2008 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For this 2008 survey, Adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. A split-sample design also was included to administer separate sets of questions to assess impairment due to mental health problems. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.

Abstract (en): The Study of Women's Health Across the Nation (SWAN), is a multi-site longitudinal, epidemiologic study designed to examine the health of women during their middle years. The study examines the physical, biological, psychological, and social changes during this transitional period. The goal of SWAN's research is to help scientists, health care providers, and women learn how mid-life experiences affect health and quality of life during aging. The data include questions about doctor visits, medical conditions, medications, treatments, medical procedures, relationships, smoking, and menopause related information. The study is co-sponsored by the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), the National Institutes of Health (NIH), and the NIH Office of Research on Women's Health. The study began in 1994. Between 1999 and 2001, 2,710 of the 3,302 women that joined SWAN were seen for their third follow-up visit. The research centers are located in the following communities: Detroit, Michigan; Boston, Massachusetts; Chicago, Illinois; Oakland and Los Angeles, California; Newark, New Jersey; and Pittsburgh, Pennsylvania. SWAN participants represent five racial/ethnic groups and a variety of backgrounds and cultures. ICPSR data undergo a confidentiality review and are altered when necessary to limit the risk of disclosure. ICPSR also routinely creates ready-to-go data files along with setups in the major statistical software formats as well as standard codebooks to accompany the data. In addition to these procedures, ICPSR performed the following processing steps for this data collection: Created variable labels and/or value labels.; Created online analysis version with question text.; Checked for undocumented or out-of-range codes.. Presence of Common Scales: Raw data can be used to create CES-D and SF-36 scores. Response Rates: 16,065 completed the screening interview. 3,302 were enrolled in the longitudinal study. 2,881 completed the first follow-up visit. 2,748 completed the second follow-up visit. 2,710 completed the third follow-up visit. Datasets:DS1: Study of Womens Health Across the Nation (SWAN): Visit 03 Dataset, [United States], 1999-2001 Women age 40 through 55, living in designated geographic areas, with the ability to speak English or other designated languages (Japanese, Cantonese, or Spanish), who had the cognitive ability to provide verbal informed consent, and had membership in a specific site's targeted ethnic group. Smallest Geographic Unit: None Site-specific sampling frames were used and encompassed a range of types, including lists of households, telephone numbers, and individual names of women. 2019-05-29 This data collection has been enhanced in the following ways. The title of the study was updated to match current ICPSR standards. Variable labels have been revised to spell out abbreviations and acronyms, and to correct prior misspellings. The variables in the dataset have also been reordered to match the documentation provided by the Principal Investigator. A fuller version of the question text pertaining to individual variables was completed, and now available in the ICPSR codebook. An additional document was included in this release that lists all the publications based off of the SWAN data series. Lastly, the study is now available for online analysis.2018-08-22 The data were updated to adjust missing values.2014-02-12 This data collection is now publicly available. Funding institution(s): United States Department of Health and Human Services. National Institutes of Health (NR004061). United States Department of Health and Human Services. National Institutes of Health. National Institute on Aging (AG012495, AG012505, AG012539, AG012546, AG012553, AG012554). United States Department of Health and Human Services. National Institutes of Health. National Institute of Nursing Research (AG012535). United States Department of Health and Human Services. National Institutes of Health. Office of Research on Women's Health (AG012531). face-to-face interview self-enumerated questionnaire

Data source description - Adults: NHIS monitors the health of the U.S. population by collecting and analyzing data on a broad range of health topics. Interviews are conducted continuously throughout the year, and are initiated in-person, with telephone follow-up. NHIS focuses on the health of children and adults in the United States. One adult household member is randomly selected to be the subject of a detailed health interview. If children are present, one child is also randomly selected. Adults answer on their own behalf, while a knowledgeable adult answers on behalf of the selected child. NHIS topics featured include adult life satisfaction, anxiety, depression, mental health conditions, mental health care, and social and emotional support.

Data source description - Teenagers: NHIS-Teen was a web-based health survey of teenagers between the ages of 12 to 17. Answers from teenagers helped paint a picture of the health of teenagers living in the United States. NHIS-Teen covered questions on a variety of health topics, including doctor visits, mental health, and social and emotional support. Data were collected between July 2021 and December 2023. 

For additional information, please see: https://www.cdc.gov/mental-health/about-data/mental-health-data-sources.html" target ="_blank">Mental Health Data Sources.